Evidence map›Paper›PMID 30867054›Full record

ArticleStem cell research & therapy2019

A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors.

Dasa Bohaciakova, Marian Hruska-Plochan, Rachel Tsunemoto, Wesley D Gifford, Shawn P Driscoll, Thomas D Glenn, Stephanie Wu, Silvia Marsala, Michael Navarro, Takahiro Tadokoro and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Vesicular Glutamate Release from Feeder-FreehiPSC-Derived Neurons.International journal of molecular sciences · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Dasa BohaciakovaDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Marian Hruska-PlochanDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Rachel TsunemotoGene Expression Laboratory, Howard Hughes Medical Institute and Salk Institute for Biological Studies, 10010 North Torrey Pines Rd, La Jolla, CA, 92037, USA.
Wesley D GiffordGene Expression Laboratory, Howard Hughes Medical Institute and Salk Institute for Biological Studies, 10010 North Torrey Pines Rd, La Jolla, CA, 92037, USA.
Shawn P DriscollGene Expression Laboratory, Howard Hughes Medical Institute and Salk Institute for Biological Studies, 10010 North Torrey Pines Rd, La Jolla, CA, 92037, USA.
Thomas D GlennGene Expression Laboratory, Howard Hughes Medical Institute and Salk Institute for Biological Studies, 10010 North Torrey Pines Rd, La Jolla, CA, 92037, USA.
Stephanie WuDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Silvia MarsalaDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Michael NavarroDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Takahiro TadokoroDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
Stefan JuhasInstitute of Animal Physiology and Genetics, v.v.i., AS CR, Liběchov, Czech Republic.
Jana JuhasovaInstitute of Animal Physiology and Genetics, v.v.i., AS CR, Liběchov, Czech Republic.
Oleksandr PlatoshynDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA.
David PiperPrimary and Stem Cell Systems, Life Technologies (Thermo Fisher Scientific), 501 Charmany Drive, Madison, WI, 53719, USA.
Vickie ShecklerSanford Stem Cell Clinical Center, University of California San Diego, La Jolla, CA, 92093, USA.
Dara DitsworthDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, 92093, USA.
Samuel L PfaffGene Expression Laboratory, Howard Hughes Medical Institute and Salk Institute for Biological Studies, 10010 North Torrey Pines Rd, La Jolla, CA, 92037, USA. pfaff@salk.edu.
Martin MarsalaDepartment of Anesthesiology, University of California San Diego School of Medicine, La Jolla, CA, 92093, USA. mmarsala@ucsd.edu.
University of California, San Diego · USSalk Institute for Biological Studies · USCzech Academy of Sciences, Institute of Animal Physiology and Genetics · CZHoward Hughes Medical Institute · USSanford Consortium for Regenerative Medicine · USThermo Fisher Scientific (United States) · US

Funding

Genetic and Functional Characterization of Astrocyte Subtypes in the Spinal CordF32NS093938 · NINDS · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI GLENN, THOMAS D · 2015 to 2018
$173k
NINDS NIH HHS F32 NS093938
6 · The paper itself

Abstract

backgroundA well-characterized method has not yet been established to reproducibly, efficiently, and safely isolate large numbers of clinical-grade multipotent human neural stem cells (hNSCs) from embryonic stem cells (hESCs). Consequently, the transplantation of neurogenic/gliogenic precursors into the CNS for the purpose of cell replacement or neuroprotection in humans with injury or disease has not achieved widespread testing and implementation.

methodsHere, we establish an approach for the in vitro isolation of a highly expandable population of hNSCs using the manual selection of neural precursors based on their colony morphology (CoMo-NSC). The purity and NSC properties of established and extensively expanded CoMo-NSC were validated by expression of NSC markers (flow cytometry, mRNA sequencing), lack of pluripotent markers and by their tumorigenic/differentiation profile after in vivo spinal grafting in three different animal models, including (i) immunodeficient rats, (ii) immunosuppressed ALS rats (SOD1

resultsIn vitro analysis of established CoMo-NSCs showed a consistent expression of NSC markers (Sox1, Sox2, Nestin, CD24) with lack of pluripotent markers (Nanog) and stable karyotype for more than 15 passages. Gene profiling and histology revealed that spinally grafted CoMo-NSCs differentiate into neurons, astrocytes, and oligodendrocytes over a 2-6-month period in vivo without forming neoplastic derivatives or abnormal structures. Moreover, transplanted CoMo-NSCs formed neurons with synaptic contacts and glia in a variety of host environments including immunodeficient rats, immunosuppressed ALS rats (SOD1G93A), or spinally injured minipigs, indicating these cells have favorable safety and differentiation characteristics.

conclusionsThese data demonstrate that manually selected CoMo-NSCs represent a safe and expandable NSC population which can effectively be used in prospective human clinical cell replacement trials for the treatment of a variety of neurodegenerative disorders, including ALS, stroke, spinal traumatic, or spinal ischemic injury.

Indexed as

Flow CytometryCell LineHumansMultipotent Stem CellsNeural Stem CellsAmyotrophic lateral sclerosis (ALS)Bioinformatic tools to study xenograftsHuman embryonic stem cell (hESC)Neural stem cell (NSC)Spinal cordSpinal traumatic injury

Identifiers

PMID30867054
PMCPMC6417180
OpenAlexW2942175639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.